An experimental Alzheimer's drug outperforms one just approved by the FDA
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
Read more on NPR
Science - July 17, 2023 at 09:16PM - An experimental Alzheimer's drug outperforms one just approved by the FDA
Không có nhận xét nào:
Đăng nhận xét